3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Kidney Neoplasms
2
Urolithiasis
1
Stomatitis
1
Pneumoperitoneum
1
Neoplasm Metastasis
1
Lower Urinary Tract Symptoms
1
Invasive Bladder Cancer
1
Hydronephrosis
1
Gastrointestinal Stromal Tumors
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
23
Nivolumab
20
atezolizumab
10
Specimen Handling
8
Ipilimumab
8
Cyclophosphamide
8
cabozantinib
6
Magnetic Resonance Spectroscopy
6
fludarabine
5
Sorafenib
5
sargramostim
4
Trastuzumab
4
Sunitinib
4
Bevacizumab
4
lenvatinib
3
enzalutamide
3
durvalumab
3
avelumab
3
X-Rays
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
spartalizumab
2
relatlimab
2
regorafenib
2
palbociclib
2
epacadostat
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Sodium Chloride
×
Genitourinary
×
Clear all
NCT01265810
2017-11-13
COMTT
Impaqtt Foundation
Phase 3
Completed
64 enrolled